Allergan has announced the acquisition of all the assets of RetroSense Therapeutics, a private, clinical-stage biotechnology company specializing in innovative gene therapy approaches to restore vision. RetroSense's lead development program, RST-001, is a novel gene therapy for the potential treatment of retinitis pigmentosa (RP). Under the terms of the agreement, ...
Buying a membership today will give you:
To continue reading this article register now.